贝伐单抗诱导的结直肠癌肿瘤血管正常化及序贯化疗：一个有趣且仍未解决的问题。 - Suppr

Suppr

超能文献

Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open Question.

作者信息

Ottaiano Alessandro, Caraglia Michele

机构信息

Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Naples, Italy.

Department of Precision Medicine, University "L. Vanvitelli" of Naples, Naples, Italy.

出版信息

Front Oncol. 2021 Sep 24;11:751986. doi: 10.3389/fonc.2021.751986. eCollection 2021.

DOI:10.3389/fonc.2021.751986

PMID:34631590

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8497981/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d076/8497981/7265a658c014/fonc-11-751986-g001.jpg

相似文献

Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open Question.

Front Oncol. 2021 Sep 24;11:751986. doi: 10.3389/fonc.2021.751986. eCollection 2021.

Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.

BMJ Open. 2016 Jun 2;6(6):e011454. doi: 10.1136/bmjopen-2016-011454.

(99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.

J Nucl Med. 2011 Nov;52(11):1786-94. doi: 10.2967/jnumed.111.092650.

Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.

World J Gastroenterol. 2016 Jul 21;22(27):6287-95. doi: 10.3748/wjg.v22.i27.6287.

Integration of novel agents in the treatment of colorectal cancer.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. doi: 10.1007/s00280-004-0884-0.

Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.

Expert Rev Anticancer Ther. 2008 May;8(5):683-8. doi: 10.1586/14737140.8.5.683.

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.

Lancet Oncol. 2013 Dec;14(13):1278-86. doi: 10.1016/S1470-2045(13)70490-X. Epub 2013 Nov 11.

Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.

Int J Clin Oncol. 2020 Jul;25(7):1285-1290. doi: 10.1007/s10147-020-01657-2. Epub 2020 Mar 21.

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.

JAMA Oncol. 2019 Jan 1;5(1):83-90. doi: 10.1001/jamaoncol.2018.4465.

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

BMC Cancer. 2017 Jun 9;17(1):408. doi: 10.1186/s12885-017-3360-z.

引用本文的文献

Global research landscape of antiangiogenic therapy for colorectal cancer: a bibliometric analysis of mechanistic insights and clinical advancements.

Front Oncol. 2025 Jul 24;15:1591059. doi: 10.3389/fonc.2025.1591059. eCollection 2025.

Hypoxia-Induced Reactive Oxygen Species: Their Role in Cancer Resistance and Emerging Therapies to Overcome It.

Antioxidants (Basel). 2025 Jan 15;14(1):94. doi: 10.3390/antiox14010094.

Inhibiting autophagy selectively prunes dysfunctional tumor vessels and optimizes the tumor immune microenvironment.

Theranostics. 2025 Jan 1;15(1):258-276. doi: 10.7150/thno.98285. eCollection 2025.

The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives.

Cancers (Basel). 2024 Mar 5;16(5):1063. doi: 10.3390/cancers16051063.

Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer.

Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231178403. doi: 10.1177/15330338231178403.

Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients.

J Cancer Res Clin Oncol. 2023 Aug;149(9):6435-6444. doi: 10.1007/s00432-023-04623-3. Epub 2023 Feb 10.

Selective Enhancing Blood Flow in Solid Tumor Tissue Is the Key for Achieving Satisfactory Delivery and Therapeutic Outcome of Nanodrugs via the EPR Effect.

J Pers Med. 2022 Nov 1;12(11):1802. doi: 10.3390/jpm12111802.

本文引用的文献

Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial.

JAMA Netw Open. 2021 Jul 1;4(7):e2118475. doi: 10.1001/jamanetworkopen.2021.18475.

Metabolic targeting of HIF-1α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer.

Oncogene. 2020 Jan;39(2):414-427. doi: 10.1038/s41388-019-0999-8. Epub 2019 Sep 2.

Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs.

CPT Pharmacometrics Syst Pharmacol. 2016 Nov;5(11):636-645. doi: 10.1002/psp4.12142. Epub 2016 Nov 14.

Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians.

Cancers (Basel). 2016 Aug 31;8(9):81. doi: 10.3390/cancers8090081.

The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance.

Oncotarget. 2016 Aug 30;7(35):57197-57212. doi: 10.18632/oncotarget.11084.

Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging.

PLoS One. 2015 Nov 13;10(11):e0142876. doi: 10.1371/journal.pone.0142876. eCollection 2015.

Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.

Oncotarget. 2015 Nov 10;6(35):38166-80. doi: 10.18632/oncotarget.6241.

The consensus molecular subtypes of colorectal cancer.

Nat Med. 2015 Nov;21(11):1350-6. doi: 10.1038/nm.3967. Epub 2015 Oct 12.

Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.

Oncotarget. 2015 Oct 6;6(30):30394-407. doi: 10.18632/oncotarget.4724.

Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.

J Comput Assist Tomogr. 2011 Nov-Dec;35(6):690-6. doi: 10.1097/RCT.0b013e318230d905.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验